Jefferies initiated coverage of Foghorn Therapeutics with a Buy rating and $18 price target. Foghorn pioneers in drug development via targeting chromatin regulatory machinery, a novel approach for treating various cancer types, the analyst tells investors in a research note. The firm likes the company’s synthetic lethality mechanism and broad market potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
- Foghorn Therapeutics initiated with an Outperform at Evercore ISI
- Foghorn Therapeutics Unveils August 2024 Investor Presentation
- Foghorn Therapeutics reports Q2 EPS (45c), consensus (65c)
- Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
Questions or Comments about the article? Write to editor@tipranks.com